
CLAIMS

1. Use of a compound of Formula (I):



(I)

in which

— A represents an aryl group;

— R_1 represents:
- a hydrogen atom,
- -C(O)R in which R is a hydrogen atom, a (C_1-C_6) alkoxy group, an aryl group, a (C_3-C_6) cycloalkyl group or a (C_1-C_6) alkyl group, the said alkyl optionally being substituted by:
  - . one or more hydroxyl group(s),
  - . a benzyloxy group,
  - . a (C_1-C_6) alkoxy group, optionally substituted by an aryl, or
  - . a (C_3-C_6) cycloalkyl group,
- an optionally substituted (C_1-C_6) alkyl group;

— R_2 represents:
- a hydrogen atom,
- a halogen atom,
- a cyano group,
- a nitro group,
- a (C_1-C_6) alkyl group optionally substituted by an $-NH_2$ or else by an -NHC(O)Rb group, with Rb as defined below,
  - an -ORa group in which Ra represents:
  - . a hydrogen atom,
  - . a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl group(s), by an aryl group and/or by one or more cyano group(s),
  - . a (C_2-C_6) alkynyl group,

. an aryl group;

— R_3 represents:

- a hydrogen atom,
- a halogen atom,
- a hydroxyl group,
- a cyano group,
- an $-SCF_3$ group,
- a nitro group,
- an oxo group,
- an $-S(O)_{0-2}$-alkyl group, an $-S(O)_{0-2}$-heterocycloalkyl group, an $-O-SO_2$-aryl group optionally substituted by one or more halogen atom(s);
- an -alkylaminoalkyl or -cycloalkylaminoalkyl group, each optionally substituted on the end alkyl,
- an optionally substituted sulphonamide group,
- an aryl group or a heteroaryl group, the said group being monocyclic or polycyclic and in addition optionally being substituted by a (C_1-C_6) alkyl group, by one or more halogen atom(s) or by a (C_1-C_6) alkoxy group,
- a heterocycloalkyl group optionally substituted by a (C_1-C_6) alkyl group,
- a (C_1-C_6) alkyl group optionally substituted by:
  - one or more halogen atom(s),
  - an aryl group which can be substituted by one or more halogen atom(s) or by one or more hydroxyl group(s),
  - a heteroaryl group,
  - one or more hydroxyl group(s) which can be substituted by an aryl group itself optionally substituted by one or more halogen atom(s), or
  - a heterocycloalkyl group optionally substituted by a CO(O)Ra group or by a (C_1-C_6) alkyl group, with Ra as defined above,
- a -C(O)NRbRc group, with Rb and Rc as defined below,
- a -C(O)ORc group or an $-O-C(O)ORc$ group, with Rc as defined below,
- a (C_1-C_6) alkoxy group, optionally substituted by
  - an aminoalkyl group,
  - an aminocycloalkyl group,
  - a cycloalkyl group,
  - a heterocycloalkyl group,

- a monocyclic or polycyclic heteroaryl group,
- one or more hydroxyl group(s),
- one or more halogen atom(s),
- a (C_1-C_6) alkoxy group,
- a –C(O)ORc group, with Rc as defined below,
- a -C(O)NRbRc group, with Rb and Rc as defined below,
- an oxo group, and/or
- an aryl group, itself optionally substituted by one or more halogen atom(s), a cyano group, a (C_1-C_6) alkoxy group, an -O-haloalkyl group and/or a haloalkyl group,

■ an -O-cycloalkyl group, an -O-aryl group or an -O-heterocycloalkyl group, each optionally substituted by

- an aryl group, itself optionally substituted by one or more halogen atom(s) or by a (C_1-C_6) alkyl group,
- an oxo group,
- one or more halogen atom(s), and/or
- a (C_1-C_6) alkyl group, which can itself be substituted by an aryl group and/or an oxo group,

■ an –NH-CO-NH-aryl group, an –NH-CO-NH-heteroaryl group or an –NH-CO-NH-(C_1-C_6) alkyl group, each optionally being substituted by one or more halogen atom(s), by a cyano group, by a nitro group, by one or more hydroxyl group(s) or by a (C_1-C_6) alkoxy group,

■ an –N-(C_1-C_6) alkyl group, it being possible for the (C_1-C_6) alkyl group to be substituted by

- one or more oxo group(s), and/or
- one or more aryl group(s) optionally substituted by one or more halogen atom(s) and/or by an SO_2 group,
- an –NH-CO-aryl group or an -NH-CO-heteroaryl group, each optionally being substituted by one or more halogen atom(s);

— R_4 represents a hydrogen atom, an oxo group or a (C_1-C_6) alkyl group;

— Rb represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl, cyano, amino, heterocycloalkyl or (C_1-C_6) alkoxy group(s) or by an aryl group optionally substituted by one or more halogen atom(s),

. a (C_3-C_6) cycloalkyl group,

. a (C_2-C_6) alkynyl group,
. a (C_1-C_6) alkoxy group,
. an aryl group optionally substituted by one or more halogen atom(s);


— Rc represents a hydrogen atom or a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s);

or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group;

— m and n represent, independently of one another, the value 0, 1 or 2, it being understood that $m+n \leq 3$;

— p and p' represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R_2 groups are on separate carbon atoms and can be different from one another and, when p' is greater than or equal to 2, then the R_3 groups are on separate carbon atoms and can be different from one another;

— q represents the value 0 or 2, it being understood that, when q = 0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type:



with R_1, R_4, m and n as defined above,

— r represents the value 0 or 1;

in the form of the base or of an addition salt with an acid

in the manufacture of a medicament for treating a disorder selected from the group

consisting of Parkinson's disease and Alzheimer's disease.


2. The use of Claim 1, wherein the treating of Parkinson's disease comprises the treating and/or preventing of motor disorders, depression and/or cognitive disorders.

3. The use of Claim 2, wherein the anomalies or motor disorders are chosen from resting tremor, rigidity, bradykinesia and deficiency in postural reflexes.

4. The use of Claim 1, wherein the treating of Alzheimer's disease comprises preventing and/or treating of cognitive disorders and/or behavioural disorders.

CLAIMS

1. Use of a compound corresponding to the general formula (I)



(I)

in which

— A represents an aryl group or a heteroaryl group;

— R_1 represents:

- a hydrogen atom,
- -C(O)R in which R is a hydrogen atom, a (C_1-C_6) alkoxy group, an aryl group, a (C_3-C_6) cycloalkyl group or a (C_1-C_6) alkyl group, the said alkyl optionally being substituted by:
  - . one or more hydroxyl group(s),
  - . a benzyloxy group,
  - . a (C_1-C_6) alkoxy group, optionally substituted by an aryl, or
  - . a (C_3-C_6) cycloalkyl group,
- an optionally substituted (C_1-C_6) alkyl group;

— R_2 represents:

- a hydrogen atom,
- a halogen atom,
- a cyano group,
- a nitro group,
- a (C_1-C_6) alkyl group optionally substituted by an $-NH_2$ or else by an -NHC(O)Rb group, with Rb as defined below,
- an -ORa group in which Ra represents:
  - . a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl group(s), by an aryl group and/or by one or more cyano group(s),

. a (C_2-C_6) alkynyl group,

. an aryl group;

— R_3 represents:

- a hydrogen atom,
- a halogen atom,
- a hydroxyl group,
- a cyano group,
- an $-SCF_3$ group,
- a nitro group,
- an oxo group,
- an $-S(O)_{0\text{-}2}$-alkyl group, an $-S(O)_{0\text{-}2}$-heterocycloalkyl group, an $-O-SO_2$-aryl group optionally substituted by one or more halogen atom(s);
- an -alkylaminoalkyl or -cycloalkylaminoalkyl group, each optionally substituted on the end alkyl,
- an optionally substituted sulphonamide group,
- an aryl group or a heteroaryl group, the said group being monocyclic or polycyclic and in addition optionally being substituted by a (C_1-C_6) alkyl group, by one or more halogen atom(s) or by a (C_1-C_6) alkoxy group,
- a heterocycloalkyl group optionally substituted by a (C_1-C_6) alkyl group,
- a (C_1-C_6) alkyl group optionally substituted by:
  - one or more halogen atom(s),
  - an aryl group which can be substituted by one or more halogen atom(s) or by one or more hydroxyl group(s),
  - a heteroaryl group,
  - one or more hydroxyl group(s) which can be substituted by an aryl group itself optionally substituted by one or more halogen atom(s), or
  - a heterocycloalkyl group optionally substituted by a CO(O)Ra group or by a (C_1-C_6) alkyl group, with Ra as defined above,
- a -C(O)NRbRc group, with Rb and Rc as defined below,
- a -C(O)ORc group or an $-O-C(O)ORc$ group, with Rc as defined below,
- a (C_1-C_6) alkoxy group, optionally substituted by
  - an aminoalkyl group,
  - an aminocycloalkyl group,

- a cycloalkyl group,
- a heterocycloalkyl group,
- a monocyclic or polycyclic heteroaryl group,
- one or more hydroxyl group(s),
- one or more halogen atom(s),
- a (C_1-C_6) alkoxy group,
- a –C(O)ORc group, with Rc as defined below,
- a -C(O)NRbRc group, with Rb and Rc as defined below,
- an oxo group, and/or
- an aryl group, itself optionally substituted by one or more halogen atom(s), a cyano group, a (C_1-C_6) alkoxy group, an -O-haloalkyl group and/or a haloalkyl group,

■ an -O-cycloalkyl group, an -O-aryl group or an -O-heterocycloalkyl group, each optionally substituted by

- an aryl group, itself optionally substituted by one or more halogen atom(s) or by a (C_1-C_6) alkyl group,
- an oxo group,
- one or more halogen atom(s), and/or
- a (C_1-C_6) alkyl group, which can itself be substituted by an aryl group and/or an oxo group,

■ an –NH-CO-NH-aryl group, an –NH-CO-NH-heteroaryl group or an –NH-CO-NH-(C_1-C_6) alkyl group, each optionally being substituted by one or more halogen atom(s), by a cyano group, by a nitro group, by one or more hydroxyl group(s) or by a (C_1-C_6) alkoxy group,

■ an –N-(C_1-C_6) alkyl group, it being possible for the (C_1-C_6) alkyl group to be substituted by

- one or more oxo group(s), and/or
- one or more aryl group(s) optionally substituted by one or more halogen atom(s) and/or by an SO_2 group,

■ an –NH-CO-aryl group or an -NH-CO-heteroaryl group, each optionally being substituted by one or more halogen atom(s);

or else R_3 forms, with A, a polycyclic heteroaryl group optionally substituted by a (C_1-C_6) alkoxy group or a (C_1-C_6) alkyl group optionally substituted by an aryl group which can itself be substituted by one or more halogen atom(s);

— R_4 represents a hydrogen atom, an oxo group or a (C_1-C_6) alkyl group;

— Rb represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl, cyano, amino, heterocycloalkyl or (C_1-C_6) alkoxy group(s) or by an aryl group optionally substituted by one or more halogen atom(s),

. a (C_3-C_6) cycloalkyl group,

. a (C_2-C_6) alkynyl group,

. a (C_1-C_6) alkoxy group,

. an aryl group optionally substituted by one or more halogen atom(s);


— Rc represents a hydrogen atom or a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s);

or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group;

— m and n represent, independently of one another, the value 0, 1 or 2, it being understood that m+n≤3;

— p and p' represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R_2 groups are on separate carbon atoms and can be different from one another and, when p' is greater than or equal to 2, then the R_3 groups are on separate carbon atoms and can be different from one another;

— q represents the value 0 or 2, it being understood that, when q = 0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type:




with R_1, R_4, m and n as defined above,

— r represents the value 0 or 1;

in the form of the base or of an addition salt with an acid;

in the preparation of a medicament intended for the treatment and/or prevention of disorder(s) related to the central nervous system and/or related to the peripheral nervous system.

2. Use of a compound corresponding to the general formula (I)



(I)

in which

— A represents an aryl group or a heteroaryl group;

— R_1 represents:

- a hydrogen atom,
- -C(O)R in which R is a hydrogen atom, a (C_1-C_6) alkoxy group, an aryl group, a (C_3-C_6) cycloalkyl group or a (C_1-C_6) alkyl group, the said alkyl optionally being substituted by:
  - . one or more hydroxyl group(s),
  - . a benzyloxy group,
  - . a (C_1-C_6) alkoxy group, optionally substituted by an aryl, or
  - . a (C_3-C_6) cycloalkyl group,
- an optionally substituted (C_1-C_6) alkyl group;

— R_2 represents:

- a hydrogen atom,
- a halogen atom,
- a cyano group,
- a nitro group,

■ a (C_1-C_6) alkyl group optionally substituted by an $-NH_2$ or else by an -NHC(O)Rb group, with Rb as defined below,

■ an -ORa group in which Ra represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl group(s), by an aryl group and/or by one or more cyano group(s),

. a (C_2-C_6) alkynyl group,

. an aryl group;

— R_3 represents:

■ a hydrogen atom,

■ a halogen atom,

■ a hydroxyl group,

■ a cyano group,

■ an $-SCF_3$ group,

■ a nitro group,

■ an oxo group,

■ an $-S(O)_{0-2}$-alkyl group, an $-S(O)_{0-2}$-heterocycloalkyl group, an $-O-SO_2$-aryl group optionally substituted by one or more halogen atom(s);

■ an -alkylaminoalkyl or -cycloalkylaminoalkyl group, each optionally substituted on the end alkyl,

■ an optionally substituted sulphonamide group,

■ an aryl group or a heteroaryl group, the said group being monocyclic or polycyclic and in addition optionally being substituted by a (C_1-C_6) alkyl group, by one or more halogen atom(s) or by a (C_1-C_6) alkoxy group,

■ a heterocycloalkyl group optionally substituted by a (C_1-C_6) alkyl group,

■ a (C_1-C_6) alkyl group optionally substituted by:

- one or more halogen atom(s),

- an aryl group which can be substituted by one or more halogen atom(s) or by one or more hydroxyl group(s),

- a heteroaryl group,

- one or more hydroxyl group(s) which can be substituted by an aryl group itself optionally substituted by one or more halogen atom(s), or

- a heterocycloalkyl group optionally substituted by a CO(O)Ra group or by a (C_1-C_6) alkyl group, with Ra as defined above,

■ a -C(O)NRbRc group, with Rb and Rc as defined below,

■ a -C(O)ORc group or an –O-C(O)ORc group, with Rc as defined below,

■ a (C_1-C_6) alkoxy group, optionally substituted by

- an aminoalkyl group,
- an aminocycloalkyl group,
- a cycloalkyl group,
- a heterocycloalkyl group,
- a monocyclic or polycyclic heteroaryl group,
- one or more hydroxyl group(s),
- one or more halogen atom(s),
- a (C_1-C_6) alkoxy group,
- a –C(O)ORc group, with Rc as defined below,
- a -C(O)NRbRc group, with Rb and Rc as defined below,
- an oxo group, and/or
- an aryl group, itself optionally substituted by one or more halogen atom(s), a cyano group, a (C_1-C_6) alkoxy group, an -O-haloalkyl group and/or a haloalkyl group,

■ an -O-cycloalkyl group, an -O-aryl group or an -O-heterocycloalkyl group, each optionally substituted by

- an aryl group, itself optionally substituted by one or more halogen atom(s) or by a (C_1-C_6) alkyl group,
- an oxo group,
- one or more halogen atom(s), and/or
- a (C_1-C_6) alkyl group, which can itself be substituted by an aryl group and/or an oxo group,

■ an –NH-CO-NH-aryl group, an –NH-CO-NH-heteroaryl group or an –NH-CO-NH-(C_1-C_6) alkyl group, each optionally being substituted by one or more halogen atom(s), by a cyano group, by a nitro group, by one or more hydroxyl group(s) or by a (C_1-C_6) alkoxy group,

■ an –N-(C_1-C_6) alkyl group, it being possible for the (C_1-C_6) alkyl group to be substituted by

- one or more oxo group(s), and/or
- one or more aryl group(s) optionally substituted by one or more halogen atom(s) and/or by an SO_2 group,

■ an –NH-CO-aryl group or an -NH-CO-heteroaryl group, each optionally being substituted by one or more halogen atom(s);

or else R_3 forms, with A, a polycyclic heteroaryl group optionally substituted by a (C_1-C_6)

alkoxy group or a (C_1-C_6) alkyl group optionally substituted by an aryl group which can itself be substituted by one or more halogen atom(s);

— R_4 represents a hydrogen atom, an oxo group or a (C_1-C_6) alkyl group;

— Rb represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl, cyano, amino, heterocycloalkyl or (C_1-C_6) alkoxy group(s) or by an aryl group optionally substituted by one or more halogen atom(s),

. a (C_3-C_6) cycloalkyl group,

. a (C_2-C_6) alkynyl group,

. a (C_1-C_6) alkoxy group,

. an aryl group optionally substituted by one or more halogen atom(s);


— Rc represents a hydrogen atom or a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s);

or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group;

— m and n represent, independently of one another, the value 0, 1 or 2, it being understood that $m+n \leq 3$;

— p and p' represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R_2 groups are on separate carbon atoms and can be different from one another and, when p' is greater than or equal to 2, then the R_3 groups are on separate carbon atoms and can be different from one another;

— q represents the value 0 or 2, it being understood that, when q = 0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type:



with R_1, R_4, m and n as defined above,

— r represents the value 0 or 1;

in the form of the base or of an addition salt with an acid;

as medicament.

3. Use according to either of the preceding claims, characterized in that the disorder(s) is or are chosen from psychiatric disorders and neurological disorders.

4. Use according to Claim 3, characterized in that the psychiatric disorders are chosen from anxiety, depression, mood disorders, insomnia, delusion disorders, obsessive disorders, psychoses, disorders related to schizophrenia, attention deficit hyperactivity disorders (ADHD) in hyperkinetic children, disorders related to the use of psychotropic substances, in particular in the case of abuse of a substance and/or of dependency on a substance, including alcohol dependence and/or nicotine dependence, migraine, stress, disorders related to illnesses of psychosomatic origin, panic attacks, epilepsy, memory disorders, cognitive disorders, in particular senile dementia or disorders related to Alzheimer's disease, and disorders of attention or of vigilance, ischaemia, disorders related to brain trauma or disorders related to acute or chronic neurodegenerative diseases, including chorea and Huntington's chorea.

5. Use according to Claim 3, characterized in that the neurological disorders are reflected by movement anomalies or motor disorders associated with a pathology chosen from dyskinesia, Parkinson's disease, postencephalitic parkinsonism, dopa-sensitive dystonia, Shy-Drager syndrome, periodic limb movement disorder (PLMD) syndrome, periodic limb movements in sleep (PLMS) syndrome, Tourette's syndrome or restless legs syndrome (RLS).

6. Use according to Claim 5, characterized in that the movement anomalies or motor disorders are associated with Parkinson's disease.

7. Use according to Claim 6, characterized in that the anomalies or motor disorders are chosen from resting tremor, rigidity, bradykinesia and deficiency in postural reflexes.

8. Use according to one of Claims 4 to 7, (a) in the treatment and/or prevention of disorders related to schizophrenia, in particular (i) in the prevention and/or treatment of positive or negative symptoms and/or (ii) in the prevention and/or treatment of memory deficiency, (b) in the treatment and/or prevention of disorders associated with Parkinson's disease, in particular (i) in the symptomatic prevention and/or treatment of motor disorders, depression and/or cognitive disorders and/or (ii) in its basic treatment, and/or (c) in the treatment and/or prevention of disorders related to Alzheimer's disease, in particular (i) in the symptomatic prevention and/or treatment of cognitive disorders and/or behavioural disorders and/or (ii) in its basic treatment.

9. Use according to Claim 3, characterized in that the neurological disorders are reflected by movement anomalies or motor disorders associated with trauma of the spinal cord, in particular spinal trauma.

10. Use according to any one of the preceding claims, characterized in that A represents a phenyl group or a pyridyl group.

11. Use according to any one of the preceding claims, characterized in that q = 0, and m and n each represents 1.

12. Use according to any one of the preceding claims, characterized in that R_2 represents a (C_1-C_6) alkyl group, in particular a methyl, substituted by an –NH-C(O)-Rb group, Rb being as defined in Claim 1 or Claim 2.

13. Use according to any one of Claims 1 to 11, characterized in that R_2 represents an –ORa group, Ra being as defined in Claim 1 or Claim 2.

14. Use according to any one of Claims 1 to 11, characterized in that R_2 is a halogen atom or a cyano or a hydrogen or a hydroxyl or a (C_1-C_6) alkyl optionally substituted by an $–NH_2$ or else by an –NHC(O)Rb group, Rb being as defined in Claim 1 or Claim 2.

15. Use according to any one of Claims 1 to 11, characterized in that A is a phenyl, R_1 is a –C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1 and R_2 represents –ORa, Ra being as defined in Claim 1 or Claim 2.


16. Use according to any one of Claims 1 to 11, characterized in that A is a phenyl, R_1 is a –C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p = 1 and R_2 represents a methyl substituted by an -NH-CO-Rb group, Rb being as defined in Claim 1 or Claim 2.

17. Use according to any one of Claims 1 to 11, characterized in that A is a phenyl, R_1 is a –C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p is equal to 2, one of the R_2 groups is –ORa, Ra being as defined in Claim 1 or Claim 2, and the other of the R_2 groups is a halogen atom.

18. Use according to any one of the preceding claims, characterized in that the R_2 group is in the 6 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system and in that there may additionally be an R_2 group, identical to or different from the said abovementioned R_2 group, in the 7 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system, the said compound of formula (I) being in the base, hydrate or solvate form, in the form of isomers or in the form of their mixtures.

19. Use according to any one of Claims 1 to 9, characterized in that the compound of formula (I) is chosen from compounds Nos. 1 to 6, 11 to 14, 16, 20, 22 to 25, 32 to 43, 47 to 52, 55 to 59, 72, 74, 76, 78, 79, 89 to 91, 97, 102, 108, 111, 112, 114, 116 to 118, 124, 130, 131, 133 to 135, 143, 145, 155, 158, 160, 165 to 167, 170, 175, 178, 183 to 186, 188, 189, 190, 193, 194, 200, 201, 203, 206, 207, 212, 213, 215, 216, 218, 223, 224, 226, 228, 230, 232 to 234, 239, 240, 242, 243, 245, 246, 250, 251, 254, 258, 263, 264, 270, 275, 276, 278 to 280, 282, 283, 285 to 287, 289, 292, 294, 295, 287 to 302, 305 to 312, 315 to 345, 349 to 355, 357, 358, 360, 362, 369, 371, 373, 375 to 377, 379 to 394 and 403, in the form of the base or of an addition salt with an acid.

20. Compound corresponding to the general formula (I)



(I)

in which

— A represents an aryl group or a heteroaryl group;

— R_1 represents:

■ a hydrogen atom,

■ -C(O)R in which R is a hydrogen atom, a (C_1-C_6) alkoxy group, an aryl group, a (C_3-C_6) cycloalkyl group or a (C_1-C_6) alkyl group, the said alkyl optionally being substituted by:

. one or more hydroxyl group(s),

. a benzyloxy group,

. a (C_1-C_6) alkoxy group, optionally substituted by an aryl, or

. a (C_3-C_6) cycloalkyl group,

■ an optionally substituted (C_1-C_6) alkyl group;

— R_2 represents:

■ a hydrogen atom,

■ a halogen atom,

■ a cyano group,

■ a nitro group,

■ a (C_1-C_6) alkyl group optionally substituted by an $-NH_2$ or else by an -NHC(O)Rb group, with Rb as defined below,

■ an -ORa group in which Ra represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl group(s), by an aryl group and/or by one or more cyano group(s),

. a (C_2-C_6) alkynyl group,

. an aryl group;

— R_3 represents:

- a hydrogen atom,
- a halogen atom,
- a hydroxyl group,
- a cyano group,
- an $-SCF_3$ group,
- a nitro group,
- an oxo group,
- an $-S(O)_{0-2}$-alkyl group, an $-S(O)_{0-2}$-heterocycloalkyl group, an $-O-SO_2$-aryl group optionally substituted by one or more halogen atom(s);
- an -alkylaminoalkyl or -cycloalkylaminoalkyl group, each optionally substituted on the end alkyl,
- an optionally substituted sulphonamide group,
- an aryl group or a heteroaryl group, the said group being monocyclic or polycyclic and in addition optionally being substituted by a (C_1-C_6) alkyl group, by one or more halogen atom(s) or by a (C_1-C_6) alkoxy group,
- a heterocycloalkyl group optionally substituted by a (C_1-C_6) alkyl group,
- a (C_1-C_6) alkyl group optionally substituted by:
  - one or more halogen atom(s),
  - an aryl group which can be substituted by one or more halogen atom(s) or by one or more hydroxyl group(s),
  - a heteroaryl group,
  - one or more hydroxyl group(s) which can be substituted by an aryl group itself optionally substituted by one or more halogen atom(s), or
  - a heterocycloalkyl group optionally substituted by a CO(O)Ra group or by a (C_1-C_6) alkyl group, with Ra as defined above,
- a -C(O)NRbRc group, with Rb and Rc as defined below,
- a -C(O)ORc group or an –O-C(O)ORc group, with Rc as defined below,
- a (C_1-C_6) alkoxy group, optionally substituted by
  - an aminoalkyl group,
  - an aminocycloalkyl group,
  - a cycloalkyl group,
  - a heterocycloalkyl group,
  - a monocyclic or polycyclic heteroaryl group,
  - one or more hydroxyl group(s),

- one or more halogen atom(s),
- a (C_1-C_6) alkoxy group,
- a –C(O)ORc group, with Rc as defined below,
- a -C(O)NRbRc group, with Rb and Rc as defined below,
- an oxo group, and/or
- an aryl group, itself optionally substituted by one or more halogen atom(s), a cyano group, a (C_1-C_6) alkoxy group, an -O-haloalkyl group and/or a haloalkyl group,

■ an -O-cycloalkyl group, an -O-aryl group or an -O-heterocycloalkyl group, each optionally substituted by

- an aryl group, itself optionally substituted by one or more halogen atom(s) or by a (C_1-C_6) alkyl group,
- an oxo group,
- one or more halogen atom(s), and/or
- a (C_1-C_6) alkyl group, which can itself be substituted by an aryl group and/or an oxo group,

■ an –NH-CO-NH-aryl group, an –NH-CO-NH-heteroaryl group or an –NH-CO-NH-(C_1-C_6) alkyl group, each optionally being substituted by one or more halogen atom(s), by a cyano group, by a nitro group, by one or more hydroxyl group(s) or by a (C_1-C_6) alkoxy group,

■ an –N-(C_1-C_6) alkyl group, it being possible for the (C_1-C_6) alkyl group to be substituted by

- one or more oxo group(s), and/or
- one or more aryl group(s) optionally substituted by one or more halogen atom(s) and/or by an SO_2 group,

■ an –NH-CO-aryl group or an -NH-CO-heteroaryl group, each optionally being substituted by one or more halogen atom(s);

or else R_3 forms, with A, a polycyclic heteroaryl group optionally substituted by a (C_1-C_6) alkoxy group or a (C_1-C_6) alkyl group optionally substituted by an aryl group which can itself be substituted by one or more halogen atom(s);

— R_4 represents a hydrogen atom, an oxo group or a (C_1-C_6) alkyl group;

— Rb represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by

one or more hydroxyl, cyano, amino, heterocycloalkyl or (C_1-C_6) alkoxy group(s) or by an aryl group optionally substituted by one or more halogen atom(s),

. a (C_3-C_6) cycloalkyl group,

. a (C_2-C_6) alkynyl group,

. a (C_1-C_6) alkoxy group,

. an aryl group optionally substituted by one or more halogen atom(s);


— Rc represents a hydrogen atom or a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s);

or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group;

— m and n represent, independently of one another, the value 0, 1 or 2, it being understood that $m+n \leq 3$;

— p and p' represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R_2 groups are on separate carbon atoms and can be different from one another and, when p' is greater than or equal to 2, then the R_3 groups are on separate carbon atoms and can be different from one another;

— q represents the value 0 or 2, it being understood that, when q = 0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type:



with R_1, R_4, m and n as defined above,

— r represents the value 0 or 1;

in the form of the base or of an addition salt with an acid;

in the treatment and/or prevention of disorder(s) related to the central nervous

system and/or related to the peripheral nervous system, the said disorder(s) being advantageously chosen from psychiatric disorders and neurological disorders.

21. Compound according to the preceding claim, characterized in that it is defined according to any one of Claims 9 to 19.